

## Subject Index

### A

**Actin**, 17

*Actinobacillus pleuropneumoniae*, 249-250  
Adherence assay, 184  
Adherence to human neutrophils, 188-189  
Adhesin gene of *Mycoplasma piritum* in AIDS patients, 279-282  
Adhesion molecules, 170  
Adjuvant cholera toxin, 219  
Adult respiratory distress syndrome, 140  
Agammaglobulinemia in children with measles virus, 114  
Aged animals, mucosal immunity in, 151-153  
Aging and depressed immune response, 151  
AIDS, 40, 279-282  
AIDS-like CD4<sup>+</sup> T-cell lymphopenia, 79  
Alloxan and diabetes mellitus, 310-311  
Alpha/beta T cells in immunity, 53-67  
Alveolar macrophages, 141  
Amphotericin B, 93-104  
Anaerobes, 183  
Anaerobic growth, 187-188, 189  
and CMP-NANA, 185-186  
Annexins, translocation of, 326-328

Antibody  
in autoimmune thyroid disease, 345-347  
levels and immunogenicity, 108  
responses, systemic, 222-224  
Antibody-secreting cells, 220  
Antigen, multiple banded, 299-301  
Antigen-specific T-cell proliferation, 225  
Antigenic variation, viral, 37-41  
Antidiotype antibodies as polysaccharide vaccines, 209-215

Apoptosis, macrophage, and *S. flexneri*, 199-201  
*Arenaviruses*, 109  
Autoimmune thyroid disease, 345-347  
Autoimmunity, 126-127

**B**  
Bacteremia, 212, 213, 214  
streptococcal, 238  
Bacterial adherence, 249-250  
and IL-6 and IL-8 secretion, 169  
and mucosal cytokine production, 162-177  
Bacterial adhesins, 162-164  
Bacterial infections and IL-8 expression, 140-141  
Bacterial killing, 283-285  
Bacterial lectins, 162-164  
Bactericidal action of serum, 192  
BALB/c mice, 210-212  
4-1BB, 119

*Bcg*, the natural resistance gene, 313-314  
Bladder infection, protection against, by stress, 302-303

Bone marrow transplantation, 76  
autologous, 238  
*Borrelia burgdorferi*, inactivated, immunization with, 364-366  
Brazilian purpuric fever, 260-262, 269-272, 297-298  
Bronchoalveolar lavage, 141  
*Brucella*, intracellular behavior of, 276-278  
Butyrate, 246-248

### C

**Candidiasis**, 75

Capsular polysaccharide, 209, 315-317  
Cardiac defect, 76  
CD18, 202  
CD27, 119  
CD3<sup>+</sup> T cells, 76-77  
CD4<sup>+</sup> helper cells, 318-321  
CD4<sup>+</sup> T cells, 225  
and *B. burgdorferi* infection, 364-366  
CD4<sup>+</sup> Th cell subset, 84  
CD4<sup>+</sup> Th1 and Th2 cells, 84  
CD40, 119  
CD8<sup>+</sup> cytotoxic cells, 318-321  
Cell biology of infection, 15-22  
Cell-mediated immune response in hepatic injury, 318-321  
Cells (see specific cell)  
Chemoattractants, 170  
Chemotactic cytokines, 136-137  
Chemotactic factors, 135-137  
Chemotherapy, infections after, 235-241  
Chick embryo model of *Neisseria meningitidis*, 266-268  
Children, Brazilian purpuric fever in, 260-262, 269-272, 297-298  
*Chlamydia trachomatis*, 304-305  
*Chlamydia trachomatis* serovar L2 in HeLa and McCoy cells, 326-328  
Chlamydial persistence, 304-305  
Cholera toxin, adjuvant, 219  
Class II MHC and foreign peptide binding, 338-341  
Class II MHC antigens, 275  
CMP-NANA (cytidine monophospho-N-acetyl neuraminic acid), 183, 187, 188, 190-194  
Coevolution of TNF receptors and ligands, 121-123  
Colon in shigellosis, 197  
Complement Clq and attachment of gonococcal cells to uterus, 292

Computerized image analysis, 287  
Conotruncal cardiac defects, 76  
CTL epitope map of lymphocytic choriomeningitis virus, 110  
CTL epitopes, 110-111  
Cytokine balance, 74  
Cytokine networks, 136-137  
Cytokine patterns in leprosy, 42-49  
Cytokine production  
and acute endotoxemia, 336-337  
in macrophages, 313-314  
mucosal, and bacterial adherence, 162-177  
Cytokine response in *Neisseria gonorrhoeae* infection, 322-324  
Cytokines, 42-49, 67, 73, 74, 85, 128, 136-137, 162, 166-169, 176-177, 200-201, 239-240, 313-314, 336-337  
and hepatitis A virus, 318-321  
combined, 239-240  
detection of, 43-44

**D**eath domain, 121  
Dehydroepiandrosterone (DHEA), 145  
Dense granule proteins, 2, 4  
Diabetes mellitus, alloxan-induced, 310-311  
Diarrhea, 197  
DiGeorge syndrome, 76-78  
Digital confocal microscopy, 287  
1,25 Dihydroxyvitamin D<sub>3</sub> (1,25(OH)<sub>2</sub>D<sub>3</sub>), 147  
Disseminated gonococcal infection (DGI), 8, 10-11  
DNA supercoiling, 187-188  
Duplication of TNF receptor gene, 122  
Dysentery, 197

**E**lISPOT, 225-227  
Endotoxemia  
and cytokine production, 336-337  
and nitric oxide, 329-330  
Enrichment protocol, 29  
Enrichment scheme, limitation of, 33-34  
Epithelial cells, 201  
Epithelium  
*Escherichia coli* in, 286-289  
in shigellosis, 197  
Escape into cytoplasm, 33  
*Escherichia coli*  
and short chain organic acid butyrate, 246-248  
enterohemorrhagic, 310-311  
fimbriae in pregnancy with pyelonephritis, 290  
in fallopian tube epithelium, 286-289  
killing of, by polymorphonucleocytes, 283-285  
recolonization with, 243-245  
uropathogenic, 162-177

Evolution, hormones in, 118  
**F**allopian tube epithelium, 286-289  
Fas, 119  
Fast neutron irradiated cells and *Salmonella typhi*, 348-349  
Fimbriae, 162-164  
Flow microfluorimetry, 273-275  
Fungal infections and amphotericin B, 93-104

**G**alE gene, 252-254  
Gamma/delta T cells in immunity, 53-67  
Gamma interferon, 84  
in chlamydial growth, 304-305  
Generalized lymphoproliferative disease (Gld), 124-126  
Genes (see also specific gene)  
function regulated by steroid hormones *in vivo*, 159  
in *Mycobacterium tuberculosis*, 263-265  
in resistance of mycobacteria to killing by macrophages, 26  
virulence-related, 295-296  
Gestational pyelonephritis, *E. coli* fimbrial types in, 290-291  
Globoseries of glycolipids, 164-165  
Glycolipids, 164-165  
Gonococcal cells, attachment of, to uterus, 292-293  
Gonorrhea, 7-14, 182-185, 286-289, 292, 322-324  
transmission of, 9  
Granulocyte-macrophage colony-stimulating factor, 236-238, 240  
Growth factors, hematopoietic, for infections, 235-241

**H**aemophilus influenzae biogroup aegyptius, 269-272, 297-298  
*Haemophilus influenzae*, f169 mutation of, 255-256  
HeLa cells, 326-328  
Heat shock proteins, 246  
Hematopoietic growth factors for infections, 235-241  
Hemolysin, 15  
Hepatic injury, nitric oxide in, 329-330  
Hepatitis A virus, 318-321  
Hepatitis B, chronic, 74  
HIV-1, 39-40  
HMEC-1 tissue culture cells, 269-272  
Hormonal immunomodulation, 147-150  
Hormones in evolution, 118  
Host defenses and pathogenic *Neisseria*, 182-195  
Hypoparathyroidism, 76

**I**69 mutation of *Haemophilus influenzae*, 255-256  
iC3b, 7  
ICAM, kinetics of, 170-176  
*icsA* genes, 198  
Idiotopes, 209  
Immune deficiency  
disorders of, 74-76  
thymic factors in, 71-80  
Immunity  
induced by porins from *S. typhi*, 350-352  
innate and acquired, 53-67, 84-90  
protective, 215  
using minigenes, 107-115  
Immunization (see also Vaccines)  
against *S. typhi*, 348-349  
oral, with tetanus toxoid, 219-232  
Immunoaberrant patients, 307-309  
Immunoglobulin A, 220-221  
Immunosuppressive virus and persistent infection, 113-114  
Inappropriate vaccination, 107  
Increased resistance to killing, 32-33  
Infection, 76  
after chemotherapy, 235-241  
and cytokine response, 322-324  
bladder, 302-303  
by hepatitis A virus, 318-321  
cell biology of, 15-22  
fatal, in children, 260-262, 269-272, 297-298  
fungal, 93-104  
interleukin-8 in, 134-141  
mycobacterial, 313-314  
resistance to, and T cells, 66-67  
*S. viridans* in, in Mauritius, 332-334  
with *B. burgdorferi*, 364-366  
Infectious diseases, 37 (see also specific diseases)  
vaccination for, 158-159  
Inflammation, 134, 197  
Inflammatory bowel disease, recolonization therapy in, 243-245  
Inflammatory cytokine response in infection, 322-324  
Inflammatory cytokines, 200  
Influenza-specific antibody-secreting cells, 152  
Influenza-specific secretory immunoglobulins, 151  
Inhibition of phagosome-lysosome fusion, 33  
Innate immune response, 85  
Integrins, 201  
Interleukin-1, 66-67, 166, 200  
Interleukin-1 alpha, 134  
Interleukin-1 beta, 134, 322-324  
Interleukin-2, 74  
Interleukin-3, 236, 238, 240  
and GM-CSF, 239-240  
Interleukin-4, 139, 226  
Interleukin-4+ lymphocytes in hepatitis A virus, 318-321  
Interleukin-5, 227  
Interleukin-6, 166, 169, 200, 236, 322-324  
production in *Legionella* infection, 342-343  
Interleukin-6+ lymphocytes in hepatitis A virus, 318-321  
Interleukin-7, 46  
Interleukin-8, 169, 322-324  
in infectious process, 134-141  
Interleukin-10, 139  
Interleukin-12, 46-66-67  
Interleukins, 73  
Intracellular pathogens, 15, 27  
Intracellular survival, 27, 276-278  
Intralipid and amphotericin B, 101-103  
Invariant chain dissociation from class II MHC, 338-341  
Invasion genes, 28  
Invasiveness of *Shigella flexneri*, 197-198  
*ipa* genes, 198  
Iron dextran, 210-211  
**J**774 cells, 20, 273-275  
Jarisch-Herxheimer reaction, 1  
**K**inetics of survival in macrophages, 29  
*Klebsiella pneumoniae*, 315-317  
Kupffer cells, 137  
**L**-AmpB, renal cytotoxic effects of, 93-94, 96  
*Legionella* infection, 342-343  
*Legionella pneumophila* infected macrophages and nitric oxide, 342  
*Leishmania major*, 84-90  
Leishmaniasis, 88-90  
Lentiviruses, 39-40  
Leprosy, 26-34, 42-49  
cytokine patterns in, 42-49  
Leukotoxin nonproducing mutant of *P. haemolytica*, 283-285  
Lipoooligosaccharides, 8, 10, 186, 189-190  
gonococcal, 183  
phenotypes, 192-194  
Lipopolysaccharides, 168, 200, 250, 252-254  
Lipoproteins, serum, and amphotericin B, 94  
*Listeria*, 63  
intracellular behavior of, 276-278  
*Listeria monocytogenes*, 21-22, 127  
fluorescent labeling of, 273-275  
infection, cell biology of, 15-22

LLC PK1 renal cells and amphotericin B, 98-101  
LT-alpha and LT-beta, 119  
Lung macrophages and endotoxin, 336-337  
Lyme disease, 364-366  
Lymphocytic choriomeningitis virus, 109  
Lymphoid malignancies, 238  
Lymphoid solitary nodules, 201  
Lymphokines, 145  
Lymphoma, 239  
Lymphopenia, 79  
Lymphoproliferation (*Lpr*), 124  
Lymphotoxin, 119

**M** cells and mucosal immune response, 199  
Mac 1, 202  
Macrophages, 199-201  
cytokine and nitric oxide production by, 336-337  
*L. pneumophila* in, in infection, 342-343  
resistance of mycobacteria to killing by, 26-34  
Mauritius, *S. viridans* infections in, 332-334  
McCoy cells, 326-328  
Measles vaccination, 107  
Melioidosis, 140  
Methylamine, 9  
MHC link among ligand family members, 121  
Midline defects, 76  
Minigenes, protective immunity using, 107-115  
MØ cell-associated TNF $\alpha$ , 307-309  
Monoclonal immunoglobulin A, 356-357  
Monocyte-derived neutrophil chemotactic factor (MDNCF), 135  
Mononuclear cell infiltration, 135  
mRNA subtractive hybridization, 269-272  
Mucosal antibody responses to tetanus toxoid and cholera toxin, 220  
Mucosal cytokine production and bacterial adherence, 162-177  
Mucosal cytokines, uroepithelial cells as source of, 168-169  
Mucosal immune response, 356-357  
and M cells, 199  
Mucosal immunity, induced, 353-355  
Mucosal infections, 162  
Mucosal secretions, secretory antibodies in, 144-145  
Mucosal surfaces, acquiring pathogens through, 218  
Mucus, 249-250  
Mutations distinguish TNF-alpha and LT-alpha, 122  
*mviA*, 295-296  
*mxi* genes, 198  
Mycobacteria, 313-314

Mycobacteria killing by macrophages, 26-34  
*Mycobacterium leprae*, 26-34, 42-49  
*Mycobacterium leprae* cosmid library, 30-31  
*Mycobacterium leprae* plasmid library, 31-32  
*Mycobacterium tuberculosis*, 26-34

**N**-end rule, 22  
*N*-monomethyl-L-arginine as nitric oxide inhibitor, 342-343  
Natural killer cells, 74, 87-88  
Natural resistance gene, *Bcg*, 313-314  
*Neisseria gonorrhoeae*, 182-195, 322-324  
infection of uterine endometrium by, 292  
opacity-associated proteins, 286-289  
serum resistance of, 7-14  
*Neisseria meningitidis*, 252-254, 257-259, 266-268  
*Neisseria meningitidis* serogroup C polysaccharide, 210-215  
Neisserial major outer membrane proteins, 367-369  
Neisserial porins, 367-369  
Nephrotoxicity of amphotericin B, 93-104  
Neutralizing antibody, 213  
Neutrophil granules, 184  
Neutrophil influx, 169-176  
Neutrophil lysosomal enzymes, 191  
Neutrophil migration, 170-171  
Neutrophil-dependent chemokine expression, 137-139  
New generation vaccines, 114  
Nitric oxide  
and acute endotoxemia, 336-337  
in hepatic injury after acute endotoxemia, 329-330  
in *Legionella pneumophila* infected macrophages, 342  
Nonobese diabetic mice, 126-127  
Nucleoprotein particle-amplified antigen, 353-355  
NZB mice, 126-127  
NZW mice, 126-127

**O**paicy-associated (Opa) proteins, 183, 190, 191, 286  
Opsonization of *K. pneumoniae*, 315-317  
Oral delivery systems, 217-232  
microspheres as, for tetanus toxoid, 230  
Oral vaccine models, 217-232  
Organelle association with parasitophorous vacuole membrane, 3  
Oxygen-dependent killing mechanisms, 27  
Oxygen-independent killing mechanisms, 27

**P** fimbriae, 162-164  
Paracrine and autocrine interactions, 138  
Parasitophorous vacuole membrane, 1-4  
Parathyroid dysfunction, 75  
*Pasteurella haemolytica*, 283-285  
Pathogens (see specific pathogen)  
Pathogen-macrophage interaction, 26  
Pathogens acquired through mucosal surfaces, 218  
Pelvic inflammatory disease, 9  
Pelvic tissue, attachment of gonococcal cells to, 292-293  
Peptide binding and invariant chain dissociation, 338-341  
Perfringolysin O, 19  
Permeability of parasitophorous vacuole membrane, 3  
Peyer's patch, CD4<sup>+</sup> T cells isolated from, 225  
Peyer's patches, 201  
PGE<sub>2</sub> in MØ supernatants, 307-309  
PGE<sub>2</sub> resistance to cell-associated TNF alpha, 307-309  
Phagocytic killing, 188, 190, 193  
Phagocytic killing assay, 184  
Phagocytosis, 27, 33  
and *K. pneumoniae* serotypes, 315-317  
Pneumococcal surface protein A, 361-362  
Pneumonia in cattle, 283-285  
Point mutation, 38  
Poly D-L-lactide-co-glycolide microspheres, 228  
Polymerase chain reaction, 44  
Polymorphonuclear leukocytes, 135  
Polymorphonucleocytes  
and *Pasteurella haemolytica*, 283-285  
and *S. flexneri* invasion, 201-202  
Polysaccharides, 209  
as test antigen, 367-369  
Porins from *S. typhi* in inducing immunity, 350-352  
Pregnancy, pyelonephritis in, 290-291  
Prethymic precursor T cells, 72  
Profilin, 17  
Proinflammatory cytokines, 176-177  
Prolactin receptor, 73  
Protective epitopes of pneumococcal surface protein A, 361-362  
Protective immunity, 224  
Proteins (see also specific protein), 2, 4, 8, 10-11, 127, 138, 162-164  
Pyelonephritis in pregnancy, 290-291

**R** eceptor/ligand couples, 121  
Recolonization therapy with *E. coli*, 243-245  
Recombinant cytokine-binding proteins, 127  
Recombinant *S. typhimurium*, oral immunization with, 230  
Recombinant viral vaccines, 108  
Reduction modifiable protein (Rmp), 8, 10-11  
Reflorastation in inflammatory bowel disease, 243-245  
Repressor proteins, 138  
Respiratory syncytial virus infection, 79  
Retroviruses, 39-40  
Rhoptry proteins, 2, 4  
Ribosomes in vaccine delivery system, 353-355  
Route of administration in immunization, 227

**S** fimbriae, 163  
Salicylate in *K. pneumoniae*, 315-317  
*Salmonella typhi*  
and fast neutron irradiated cells, 348-349  
in protective immunity, 350-352  
*Salmonella typhimurium*, 295-296  
fluorescent labeling of, 273-275  
Secretory antibodies in mucosal secretions, 144-145  
Secretory IgA (S-IgA), 218  
Sequence-based analysis of evolution of ligand and receptor molecules, 123  
Serum bactericidal assay, 184  
Serum killing, 182, 185  
Serum lipoproteins and amphotericin B, 94  
Serum resistance, 186  
Shedding, uroepithelial, in bladder infection, 302-303  
*Shigella flexneri*  
2a, 359-360  
lipopolysaccharide, 356-357  
tissue invasion by, 197-205  
*Shigella* vaccine, 353-355  
Shigellosis, 197-205

Stress in protecting against bladder infection, 302-303

String-of-beads vaccine, 112-113

Supercoiling of gonococcal DNA and anaerobic growth, 187-188

Synthetic peptide vaccines, 108

**T** cells  
and resistance to infection, 66-67  
in innate and acquired immunity, 53-67  
in leprosy lesions, 42

T helper cell responses in systemically immunized mice, 227-228

T-84 cell line, 201

T-cell cytokines, 176-177

T-cell function and steroid hormones, 146-147

T-cell lymphokine production, 144-159

T-cell presented peptides, binding of, 338-341

T-cell proliferation, antigen-specific, 225

T-cell receptors, 53  
in leprosy, 47-48

T-dependent antigen, 209

T-helper type 1 or 2, 74

T-independent antigens, 209

TCR  $\alpha\beta$  double-negative cells, 48

TCR  $\gamma\delta$  cells, 48

Tetanus toxoid, 217-232

TGF beta downregulation, 307-309

Thymic factors in immune deficiency, 71-80

Thymic hypoplasia, 75

Thymosin alpha 1, 73

Thymosin fraction 5, 73

Thymulin, 73

Thymus and immunity, 71-80

Tissue culture invasion assays for *N. meningitidis*, 257-259

Tissue culture model for studying Brazilian purpuric fever, 260

Tissue invasion by *Shigella flexneri*, 197-205

TNF alpha production, 307-309

TNF ligand and receptor families, origins of, 118-128

TNF/NGF family of receptors, 121

*Toxoplasma gondii*, 1-4

Transcriptional levels, 139

Transmigration of polymorphonucleocytes, 201

Trypsin, 7

Tryptophan in gamma interferon-mediated chlamydial persistence, 304

Tuberculosis, pathogenesis of, 263-265

Tumor necrosis factor, 200-201

Tumor necrosis factor alpha, 118, 134, 166, 322-324

**U**937, 276-278

*Ureaplasma urealyticum*, 299-301

Urethritis, 9

Urinary tract infections, 162

Uroepithelial cells, 176-177

Uroepithelial shedding in bladder infection, 302-303

**V**accination  
inappropriate, 107  
measles, 107  
parenteral, with weak antigen, 353-355

Vaccine adjuvants with natural regulators of T-cell lymphokine production *in vivo*, 144-159

Vaccines  
neisserial major outer membrane proteins in, 367-369

oral, 217-232

polysaccharide, 209-215

string-of-beads, 112-113

synthetic peptide, 108

Viral antigenic variation, 37-41

Viral infections, 123-124

Virulence, 297-298

Virulence-related gene regulation in *S. typhimurium*, 295-296

Virus, hepatitis A, 318-321

Viruses, 37-41, 74, 79, 108, 109, 123-124, 318-321 (see also specific virus)  
survival strategies of, 38-39

**Y**ersinia enterocolitica, 345-347

**Z**inc, 73

## Index of Contributors

**A**brams, R. S., 243-245

Ades, E. A., xiii, 260-262

Agace, W., 162-181

Amano, F., 313-314

Apicella, M. A., 209-216

Araneo, B. A., 144-161

Aronson, M., 302-303

Asher, L. V. S., 318-321

**B**ahraoui, E., 279-282

Barteneva, N. S., 345-347

Beatty, W. L., 304-306

Beckers, C. J. M., 1-6

Bélanger, M., 249-251

Belanger, T. A., 304-306

Benjamin, W. H., Jr., 295-296

Bermudes, D., 1-6

Beutler, B., 118-133

Binn, L. N., 318-321

Birkness, K. A., 257-259, 266-268

Blake, M. S., 7-14

Blanchard, A., 279-282, 299-301

Briles, D. E., 361-363

Bryla, D., 359-360

Bunning, V. K., 273-275

Byrne, G. I., 304-306

**C**ampagnari, A. A., 209-216

Canarelli, B. S., 279-282

Cao, Z., 299-301

Caron, E., 276-278

Cassell, G. H., 299-301

Cavaillon, J. M., 356-358

Chatfield, S. N., 217-234

Chretien, P. B., 71-83

Cross, A. S., 315-317, 322-325

Cunha, B. A., 315-317

Cunningham-Rundles, S., 71-83

**D**aibata, M., 338-341

Dalal, E., 302-303

Daynes, R. A., 144-161

Deal, C. D., 322-325

Desai, A. A., 304-306

Dima, F. V., 310-312, 348-349

Dima, S. V., 310-312, 348-349

Domenico, P., 315-317

Dubremetz, J. F., 1-6

Dubreuil, D., 249-251

**E**gorova, T. P., 353-355

Ernst, J. D., 326-328

Espejo, R., 338-341

Evstafieva, A. G., 345-347  
Ewing, E. P., Jr., 266-268

**F**elser, J. M., 235-242

Ferris, S., 279-282

Fischer, A., 364-366

Flores, G., 292-294

Folks, T. M., 37-41

Frangipane, J. V., 182-196

Frey, A. B., 364-366

Friedman, H., 342-344

Froshauer, S., 283-285

**G**eorge, V. G., 257-259, 260-262

Giardina, P., 209-216

Gilley, R. M., 217-234

Glass, J. I., 299-301

González, C. R., 350-352

Gorby, G., 286-289

Gordon, J. A., 283-285

Gorelov, V. N., 345-347

Gotschlich, E. C., 7-14

Guilfoyle, D. E., 246-248

Guirguis, S., 71-83

Gulati, S., 7-14

**H**arari, O., 302-303

Harbison, M., 71-83

Harrigan, M. B., 283-285

Hart, A., 290-291

Heck, D. E., 329-331

Hedges, S., 162-181

Hirshfield, I. N., 246-248

Hudson, M. E., 217-234

Huerre, M., 356-358

Humphreys, R. E., 338-341

Hwang, S. M., 329-331

**I**sbasi, A., 350-352

Ivanov, D., 348-349

**J**ackson, R. J., 217-234

Jacques, M., 249-251

Jani, D. B., 7-14

Jennings, M. P., 252-254

Jhaver, K., 307-309

Joiner, K. A., 1-6

Jones, S., 15-25

**K**aufmann, M., 356-358

Kaul, A., 292-294

Kempf, M. C., 299-301

Kihlström, E., 326-328

Kikuta-Oshima, L. C., 263-265

King, C. H., 263-265

Kiyono, H., 217-234

Klein, T. W., 342-344

Kodys, K., 307-309

Köhler, S., 276-278

Krachenbuhl, J. P., 356-358

Kumar, D., 292-294

Kumate, J., 350-352

Kunkel, S. L., 134-143

Kuschner, R. A., 322-325

**L**aky, D., 310-312

Laskin, D. L., 329-331, 336-337

Laskin, J. D., 329-331

Levenson, V. J., 353-355

Liautard, J.-P., 276-278

Lindstedt, R., 162-181

Liu, J., 182-196

Long, E. G., 260-262

Lopez-Berestein, G., 93-106

López-Macías, C., 350-352

Lukacs, N. W., 134-143

**M**agnusson, K.-E., 326-328

Majeed, M., 326-328

Martens, M., 290-291, 292-294

Martin, N., 350-352

Maskell, D. J., 252-254, 255-256

McCann, M. L., 243-245

McDaniel, L. S., 361-363

McGhee, J. R., 217-234

McQuillen, D. P., 7-14

Medalia, O., 302-303

Michetti, P., 356-358

Miller-Graziano, C. L., 307-309

Modlin, R. L., 42-52

Montagnier, L., 279-282

Morrison, R. P., 304-306

Morse, S. A., 371-374

Moxon, E. R., 252-254, 255-256

Mundayoor, S., 26-36

Murphy, F. A., 371-374

**N**akamura, R. M., 313-314

Nelson, R. P., Jr., 243-245

Nowicki, B., 290-291, 292-294

Nowicki, S., 290-291, 292-294

**O**rtiz-Navarrete, V., 350-352

Ossorio, P. N., 1-6

**P**aniagua, J., 350-352

Pearce, K. M., 53-70

Perdomo, J. J., 197-208

Phalipon, A., 356-358

Pine, L., 266-268

Polotsky, V. Y., 359-360

Polotsky, Y. E., 318-321

Poolman, J. T., 252-254

Portnoy, D. A., 15-25

Preston, A., 255-256

**Q**uinn, F. D., 257-259, 260-262, 263-265, 266-268, 269-272

**R**ai, J., 332-335

Ralph, B. A., 361-363

Ramírez, G., 350-352

Ramsey, K. H., 322-325

Rao, T. D., 364-366

Raybourne, R. B., 273-275

Rest, R. F., 182-196, 286-289

Reyes, V. E., 338-341

Ribot, E., 257-259

Rice, P. A., 7-14

Ricketts, A. P., 283-285

Robbins, J. B., 359-360

Rodríguez-del Valle, M., 329-331

Rojo, M. P., 350-352

Rubin, L. G., 297-298

**S**alo, R. J., 315-317

Sánchez, J., 350-352

Sansonetti, P. J., 197-208, 356-358

Scharton, T., 84-92

Schneerson, R., 359-360

Schneider, H., 322-325

Schwab, J. C., 1-6

Scott, P., 84-92

Shinnick, T. M., 26-36, 263-265

Sieling, P. A., 42-52

Simon, D., 182-196, 286-289

Skeen, M. J., 53-70

Staats, H. F., 217-234

Stendahl, O., 326-328

Stephens, D. S., 257-259, 266-268

Strieter, R. M., 134-143

Svanborg, C., 162-181

Svensson, M. L., 162-181

Swords, W. E., 295-296

**T**akahashi, I., 217-234

Talukdar, R., 182-196

Teng, L.-J., 299-301

Tham, T. N., 279-282

Trofa, A. F., 322-325

**U**tt, E. A., 260-262, 269-272

**V**alacer, D., 71-83

Van Der Ley, P., 252-254

Van Huffel, C., 118-133

Vassell, R. A., 318-321

**W**asan, K. M., 93-106  
Watson, H. L., 299-301  
Wenzel, B. E., 345-347  
Westerink, M. A. J., 209-216  
Wetzler, L. M., 7-14, 367-370  
Weyant, R. S., 260-262  
White, E. H., 260-262, 266-268  
Whitton, J. L., 107-117  
Wilks, K. E., 252-254

Wizemann, T. M., 336-337  
Worley, M. J., 260-262

**X**u-Amano, J., 217-234

**Y**amamoto, Y., 342-344

**Z**heng, X., 299-301  
Ziegler, H. K., 53-70  
Zychlinsky, A., 197-208